• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Atracurium & Cis-Atracurium, Non-Depolarizing Neuromuscular Blocking Agent

    PRESS RELEASE

    Development Of Manufacturing Technology For Three Pharmaceutical Ingredients

    PRESS RELEASE

    Boots consultation rooms to become ‘safe spaces’ for patients

    PHARMACEUTICAL-JOURNAL

    Accord Healthcare addresses shortages critical ventilator medicines for COVID-19

    ACCORD-HEALTHCARE

    CF Pharma received HALAL certification

    PRESS RELEASE

    Medicines Safety Update, Volume 9, Number 3, August-September 2018

    TGA

    Mylan Lab`s Generic Atracurium Besylate Receives Approval In US

    FDA

    Mylan Labs Generic Atracurium Besylate Receives Approval In US

    FDA

    Aurobindo`s Generic Atracurium Besylate Injection Approved in USA For Anesthesia

    AUROBINDO PHARMA

    Sagent Pharmaceuticals Inc, Ongoing Class II recall of Atracurium Besylate Injection, USP, 100 mg per 10 mL (10 mg per mL), Rx Only, 10 mL Multi-Dose Vial, For Intravenous Injection, Mfd. for: Sagent Pharmaceuticals, Schaumberg, IL 60195, NDC 25021-672-10 because of Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic and GMP practices at the manufacturers site potentially impacting product sterility.

    FDA

    Sagent Pharmaceuticals Inc, Ongoing Class II recall of Atracurium Besylate Injection, USP, 50 mg per 5 mL (10 mg per mL), Rx Only, 5 mL Single-Dose Vial, For Intravenous Injection, Mfd. for: Sagent Pharmaceuticals, Schaumberg, IL 60195, NDC 25021-659-05 because of Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic and GMP practices at the manufacturers site potentially impacting product sterility.

    FDA

    Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL due to FDA Observations Pertaining toAseptic and GMP Practices at the Manufacturer’s Site Potentially Impacting Product Sterility

    FDA

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.